title: Pharmacokinetics of albendazole in New Zealand white rabbits: oral versus intraperitoneal administration.
abstract: BACKGROUND
  Recent studies from our group have shown the potent antitumor effects of albendazole (ABZ). It was hypothesized that intraperitoneal (i.p.) administration of ABZ in peritoneal carcinomatosis (PC) could lead to long exposure of tumor cells to high concentration of the drug and possibly to reduced systemic toxicity.
  
  
  METHODS
  Eight male New Zealand white rabbits were randomized into two groups, all given a single dose of ABZ 150 mg/kg suspended in 0.5% carboxymethylcellulose (CMC), either as i.p. injection, or as oral administration. The concentration of ABZ and its metabolites in plasma were determined using a high performance liquid chromatography method.
  
  
  RESULTS
  The parent drug was detected in plasma after oral and i.p. administration. The C(max) of albendazole sulphoxide (ABZ-SO) resulted in a much higher plasma concentration in the oral group (41.86 microg/ml) than in the i.p. group (16.84 microg/ml, p < 0.05). The area under the concentration over time curve of ABZ-SO in the oral group (1010.43 microg/ml/h) was also significantly higher than that of the i.p. group (528.33 microg/ml/h, p < 0.05). Compared to oral administration, the i.p. administration of an ABZ suspension led to significantly lower plasma levels of the major metabolite (ABZ-SO). This could have considerable therapeutic benefits in the regional treatment of PC.
authors.affiliation: Department of Surgery, The University of New South Wales, St. George Hospital, Kogarah, Sydney, NSW 2217, Australia.
authors.forename: Zhao-Yan
authors.initials: ZY
authors.lastname: Cai
authors.forename: Peter
authors.initials: P
authors.lastname: Galettis
authors.forename: Ying
authors.initials: Y
authors.lastname: Lu
authors.forename: David L
authors.initials: DL
authors.lastname: Morris
authors.forename: Mohammad H
authors.initials: MH
authors.lastname: Pourgholami
mesh_terms: D000284:Administration, Oral; D015766:Albendazole / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D007274:Injections, Intraperitoneal; D008297:Male; D011817:Rabbits; D011897:Random Allocation
chemical_list: D000970:Antineoplastic Agents; D015766:Albendazole; C027186:albendazole sulfoxide